In a data-driven analysis, Bill explores the mechanics behind Deep Seek’s latest disruptions and what international barriers mean for investors. Delve into a detailed discussion about the socio-economic implications of struggling regions like Gaza and the impactful voices supporting change. Plus, gain a thorough understanding of corporate strategies by examining recent revenue reports from tech giants and pharmaceutical leaders such as Eli Lilly.
He’s been seen on CNBC, the Fox News Channel, and the Fox Business Channel. His articles can be found on MarketWatch, Seeking Alpha, TheStreet.com, and many other places. He’s the author of the weekly Best Stocks Now newsletter and the inventor of the Best Stocks Now app. He’s president of Gundersen Capital Management. Here is professional money manager Bill Gundersen.
SPEAKER 04 :
And welcome to the Thursday, the Thursday, February the 6th live edition of the Best Stocks Now show with professional money manager Bill Gunderson, president of Gunderson Capital Management here with Barry Kite, our chartered financial advisor. Analysts and Boyd, we have a lot to go over today. A lot of very interesting stories in the market here today. Let’s start with where the market is at the current time. The NASDAQ is up 27 points to 19,719. The Dow is down 3 points. to 44,870. The S&P 500 is closing in on its all-time high. It’s up 10 points right now to 6,072. The small cap’s up a little bit right now. The 10-year, which had some good action yesterday, The 10-year, let’s see, is up a couple of basis points right now to 4.44, I believe. 4.44, yes. And we have crude oil down. Crude oil has been moving downwards here, $70.79. That’s good for inflation. Gold has been closing in on $3,000. It’s off a little bit today. It’s at $2,869. And over at the crypto counter, we’ve got Bitcoin down 107 right now to 97,875. So welcome to today’s Best Stocks Now show with professional money manager Bill Gunderson, president of Gunderson Capital Management, a nationwide fee-based only… firm, management firm, and we also have a lot of tools for individual investors, do-it-yourselfers, et cetera, followers all over the world, really. All shapes and sizes. Yes, and people, a lot of them participating in my daily market messages and buys and sells, et cetera. So we’re having a lot of fun with that. We really are. and really enjoying it okay so let’s pick up where we left off yesterday all right all my troubles seem so far away we had the dow up 317 points couple of big winners there nvidia really was the driver in the dow yesterday i don’t know what got into nvidia all of a sudden but it’s it’s been perking up here recently On the downside, Google was kind of the off stock yesterday. I thought it was a pretty good day for the momentum stocks. We had a big drop in interest rates yesterday, about 10 basis points. And I was reading today that the new Treasury Secretary Besant and Donald Trump, they’re just saying, the heck with the Fed. We’re going to focus on lowering that 10-year yield because the Fed does not set the 10-year. The market sets the 10-year. And there’s a lot of things you can do. To drive rates down.
SPEAKER 03 :
You can buy bonds. Yeah, you can buy bonds after 10 years.
SPEAKER 04 :
Yes, and you can do things like cutting spending and doing responsible things with your money. And so far, look, I mean, they’ve driven it down to 4.44%. And I did see quite a bit of momentum in the market yesterday. When I say momentum, I mean that’s kind of the small caps. It’s kind of the arc-like stocks, you know, some of the ones that are out there on the frontier, etc.
SPEAKER 03 :
so it’s a pretty good day yesterday well when you said 444 i was like you know looking looking back and you know basically mid-january though you know we were at 4.78 so it’s a big move i mean you know big move since essentially since the inauguration and we haven’t gotten a fed rate cut during that period of time either so
SPEAKER 04 :
Whatever Trump is doing is driving rates down. AMD was a big loser yesterday. You know, that’s going to start showing up in value, value portfolios. And I have been drafting up kind of a skeleton of maybe a potential future portfolio here that I want to run would be a value portfolio. When these really, really good stocks kind of hit rock bottom, which I think AMD probably is somewhere near there.
SPEAKER 03 :
With a forward PE ratio of 23 for that particular stock. I mean, it’s certainly palatable given it’s basically a market, really the market multiple at the moment. Yes. For earnings growth of 43% this year, 33% next year, 22% in 2027.
SPEAKER 04 :
So I am drawing up and possibly adding that to our repertoire, a deep value kind of a portfolio, which I have fun delving in that area of the market also. I like value plus momentum. That’s my sweet spot. The momentum stuff kind of ends up in the emerging growth portfolio and the incubator portfolio. What you’re trying to avoid is value traps. Yes, you don’t want value traps. Initial jobless claims rise more than expected in the last week, but when I looked at the number, it didn’t give me too much heartburn. 219,000. It rose by 11,000. I’m thinking they were probably all government workers that left their jobs not wanting to work for Trump. You know, we did have, what, 20,000 take his offer to resign? So they took the money and ran. I’m not seeing any issues here with this initial jobless claims number.
SPEAKER 03 :
I mean, it doesn’t get in terms of long-term economic, you know, issue and struggle, right? It’s when you get towards that 300,000 range. And we ticked up there, what, maybe six months ago to, like, what, maybe averaging, like, 245. And, you know, it’s come down steadily since then and been pretty stable.
SPEAKER 04 :
Yeah, and as we say over and over and over again, really the trouble in the economy is going to show up first more than likely in the jobs market. So that’s why we watch that every Thursday. I had someone write to me. This morning, is the market running out of fuel? Well, the fuel that drives the market is earnings. Earnings and interest rates. I sent him a chart of earnings going back to 2007. and going forward to 2027 with projections for this year, next year, and the year after that. And I said, I ask you, if earnings are the fuel of the market, take a look at this chart, which I sent over to him. Okay, another thing we have here today is January job cuts. Well, I’m still sitting in my chair. I’m still working. I still have my job. I didn’t lose my job. But they did rise. The number of job cups announced. And, you know, anytime I see something significant, I think we had Workday earlier this week laying off 1,700 people. I have seen quite a few. I’ve seen a lot of bad stocks trimming their payroll.
SPEAKER 03 :
I think we’re getting rid of 7,000 employees maybe, something of that nature.
SPEAKER 04 :
And the government shedding a lot, obviously. The number of job cuts announced jumped 28%. You had 49, let’s call it 50,000 in January. Yeah, in the month of January, it went up 50,000, in other words, from the previous month. But it fell 40% when you look back at January.
SPEAKER 03 :
January of last year in the lowest January job cut number since 2022 so you know in other words I mean we remember two years ago we were going through some some tech layoffs um and the challenger number jumped up a bit but yeah I mean you’re still looking at a pretty benign number in terms of uh you know yes I’m not too worried about that either um
SPEAKER 04 :
Okay, now, we didn’t get a lot of big tech earnings last night, but we did get Ford. Yeah, you know what? It’s a bellwether. We’ll take a look at it. We did get Qualcomm. That’s kind of important to tech stock. And we got Lilly. Lilly came in this morning, actually. Amazon will be after the close tonight. That’s probably one of the top five earnings reports of the quarter. We’ve got Bristol Myers already in, ConocoPhillips. We’re going to get CloudFlare. That’s a pretty important tech stock, which has been on a roll. We got Roblox this morning. We got Under Armour, Yum Brands. We got Hershey, and we’re going to get MicroTechnology.
SPEAKER 03 :
You said we’re going to be what, about halfway done or a little more than halfway done by the end of this week?
SPEAKER 04 :
Yes, I would say somewhere in the 50% to 60% area more than likely once tomorrow is over. And I would score this earnings season right now with a B+. I really would because when we started out, We were looking for 11% growth year over year, comparable quarter over comparable quarter, and now we’re up over 13%. So obviously we are beating… expectations and that growth number is going up. So you know what? You got to tip your hat to a lot of these CEOs out there that just keep growing their companies and growing earnings. That’s a great thing. Overall, S&P looking for 13% growth year over year compared to the same quarter last year. We’ll be right back. There’s a lot happening in the world also right now. And welcome back here to the second quarter of today’s Best Stocks Now show. The market’s picked up just a little bit. Palantir has become our largest holding. It wasn’t, but it’s grown into that, and it’s having another good day. It’s up 5.7% today, believe it or not. Can you believe that that thing is now $244 billion out of the starting gate in 2020 at about $8 a share? That was the low. It was $5 a share in 2022, $5 a share. It was $6 a share in 2023. Today it’s $107 per share. I would say it’s the biggest winner in the S&P 500 this year. And, you know, that was my pick. You did say that. On the NASDAQ, it’s my high-conviction pick for 2025. And so far, Bill was right again. BWRA, we call it. Working hard. Palantir is gathering steam right now. It’s up 6.2%, so that’s lifting our portfolios overall very nicely here today.
SPEAKER 03 :
Yeah, I found it interesting yesterday where, I mean, I think the stock maybe gave back 3% after being up, you know, what, almost 25% the day before, and then tacking on top of that, 5% up today.
SPEAKER 04 :
Somebody’s come in and upgraded it or something. I don’t know what the news is, but, man, that thing is gathering steam. Okay, I got two Trump… stories here next you know when i first heard the story about gaza okay america will take it over and we’ll turn it into like monaco or something like that this beautiful resort and everything i thought you know i don’t know about that and i i listened to ben shapir i listened to a lot of talk show hosts okay i have since i was a little kid believe it or not i’ve always been enamored with talk radio you’re gathering information And, yes, from different sources. And I heard Ben Shapiro, who obviously is Jewish and lives part-time or he goes to Israel a lot, he actually made a pretty good case for it and kind of convinced me that, I mean, if you look at Gaza today, it’s beyond repair. It is rubble. And, you know, to rebuild it, and for them, doesn’t seem right. I mean, that’s like rewarding bad behavior. It does seem like starting all over again, bringing in the bulldozers, is about the best idea. Of course, finding a place for these 1.7 million people, Palestinians, which many of them live already in Egypt, A lot of them live in Jordan. A lot of them live in Lebanon.
SPEAKER 03 :
Displaced people for an extended period of time.
SPEAKER 04 :
You know, it kind of made sense to me when I heard Ben Shapiro. And, you know, Ben Shapiro’s main point was, look, what we’ve been doing isn’t working. Look at the result, all right, of giving them that strip of land and just kind of leaving them alone. Look at the result, okay? And the money that’s been poured into there mostly went into building terror tunnels, et cetera. So anyways, yes, it’s a controversial subject. Yes, I have my opinions. You have your opinions. But, you know, it’s a mess right now, and what we’ve been doing has not worked out.
SPEAKER 03 :
And essentially, it’s a way to attract investment, right, to rebuild at the same time. I mean, there’s a lot of jobs. There’s a lot of, from an economic standpoint, right? I mean, there’s things to it that make sense, right?
SPEAKER 04 :
Yes, and if you keep doing the same old thing, you’re going to keep getting the same old results. So anyways, it’s thinking outside of the box, okay? You have to begin somewhere, and some fresh ideas maybe are in order. All right, DeepSeek, update on DeepSeek. You know, this is the stock that turned the market upside down two weeks ago Monday, I believe it was. Biggest hit to the NASDAQ I’ve seen, yes, since the year 2000, really. And since then, though, I’m saying that a lot of the, you know, it’s getting a little bit more tarnished along the way. Now you’ve got South Korea blocking it. Taiwan has blocked it. Our Navy, the U.S. Navy has blocked it. More and more people, more and more big, big concerns are blocking it. There’s also been a lot more scrutiny on just how much it did really cost, how many Nvidia chips they really did smuggle in. To create this. I do believe that they have broken some barriers with their artificial intelligence in making it cheaper. But when you’ve got all these people blocking it, I don’t see it. I think the way they did it. is probably more compelling than their product that they have today, which is full of Chinese propaganda. I mean, that’s just going to be the way it is. They developed it, and when you ask things of it, you’re going to get the spin from the Chinese Communist Party on a lot of those things. So we’re seeing a lot of big concerns blocking China. deep seek right now.
SPEAKER 03 :
Yeah, and you’re also giving your data to them at the same time, right? So then that’s the other kind of aspect of it where they’re using your data to fuel their model going forward.
SPEAKER 04 :
Not that our guys aren’t We’re giving Google our data, okay? We’re giving ChatGPT and Microsoft our data. But it’s a little different from giving it to China. Now, here’s another story that I’m going to follow. GE, you can’t argue that breaking it up into three pieces wasn’t a fabulous idea by Larry Culp. And from time to time, companies do spin off and split into different companies. And I think Honeywell could be a player. And if you’re looking for value plays, right, I’m going to see what Honeywell does. They have confirmed plans for a three-way split.
SPEAKER 03 :
Essentially using the GE game plan and they’re basically breaking into, I think, almost something like, you know, sounded similar to the namings of what GE broke into. Yes. So they are very similar over the years.
SPEAKER 04 :
Yeah, so Honeywell is automotive. They’re aerospace. They’re security. They’re specialty chemicals. They’re engine systems. I mean, they have a lot of irons in the fire, and I do believe that it’s a good idea. breaking the company up. And I would be interested in seeing which of those three companies may be a pretty good investment at a cheap price. I mean, if you’d have bought GE right after they broke into three, and especially invested in GE Vernova, which was the power section of GE, you’d have done very well. And even the healthcare one has done okay for GE, right? But let’s keep our eye on Honeywell on a daily basis and let’s watch that thing develop because they need to do something.
SPEAKER 03 :
It’s going to be split into three publicly listed companies once they’ve fully kind of broken it apart.
SPEAKER 04 :
Yes, and I’ve seen some very successful things come from companies that break into pieces like that. Okay, the story that we’re going to get to when we get back, I would call the biggest earnings story from last night would be Lilly. And we’re going to dig into Lilly’s numbers, their current valuation. Is it a value play? What’s the growth look like right now? We’ll be right back.
SPEAKER 05 :
Well, the top brass don’t like him talking so much. And he won’t play what they say to play.
SPEAKER 04 :
Now, back to the second half of the show.
SPEAKER 06 :
Because there’s something in the air
SPEAKER 04 :
And welcome back here to the second half of today’s Best Stocks Now show. Okay, the Dow Jones Industrial Average, I believe it has two drug stocks. I know Pfizer and Merck are in the Dow Jones Industrial Average. And I wish they would let me pick the half. Pick the stocks for the Dow. I’d kick that thing in. I’d get rid of some of that soggy stuff that’s in there and get some lively stuff in there. But I know it’s supposed to really represent the economy. But I think it should represent today’s economy a little bit more than the economy of yesteryear. That’s just my opinion. I mean, I think the perfect example is finally kicking Walgreens out, Walgreens Boots Alliance, and putting in Amazon. I mean, that should have been done a long, long, long, long time ago. kicking out Intel and putting in NVIDIA. Yeah, you know, maybe they were a little more timely with that. But let’s just take a look. Okay, so an investment in Pfizer over the last 10 years, we’re talking Pfizer here, you’ve made 2.6% a year. Well, I mean, that’s holding down the Dow’s performance, obviously. The S&P is up 19.7% per year. So I would argue that Pfizer is not a very good representative of the actual drug sector. because it should be keeping up with the S&P 500. Over the last five years, Pfizer’s gone down by 1.6% per year over the last five years. The S&P is up 16.8% per year. Now, if that’s not enough, Well, let’s just take a look. Over the last three years, Pfizer’s gone backwards by 16.8% per year. Why are we rewarding this stock by keeping it in the Dow? Now let’s take a look at Lilly’s numbers, which I would argue… deserves to be in the Dow. What’s the last breakthrough drug? Okay, the vaccine. Pfizer was there with the vaccine. And I’m going to put vaccine in quotation marks back in, what, 2020. And they and Moderna were the two big players there. But who has more drugs in their pipeline? Who has drugs of today? I would argue that these weight loss drugs are miracle drugs. RFK agrees with me. RFK Jr. says they’re miracle drugs. Over the last 10 years, an investment in Lilly has returned 31% per year. You know, Lilly’s been around for 100 years, too. It’s out of Indiana. It has run circles around the S&P 500. Lilly’s up 31% a year over the last 10 years. Pfizer, 2.6%. Who deserves to be in the Dow? Over the last five years, Lilly has delivered 44% per year, while the S&P is 16.8%. Over the last three years, Lilly is 53% per year returns, while the S&P is 11.6%. It gets a performance grade of A+. Now listen, that’s comparing Lilly against TechAll, every stock in the market. And it rises to the top. A-plus in performance grade, that’s a very, very select list of stocks. I mean, you can look that up in the Best Stocks Now app. Now, let’s compare the size.
SPEAKER 03 :
Well, in all of your pharmaceutical companies, the ones that have been around long-term and who have kind of driven – usually driven by certain drugs here and there, whether it was Prozac years ago, and then you got into all the Lipitor and Crestor, and then you moved on to all of the famous ones over the years, and you need that big kind of money revenue driver because that ends up being your fuel for other R&D. And for Pfizer, they focused on cancer side, but they don’t have that The reason they have an eight forward PE multiple, right, is because they don’t have that next, you know, what’s that next big growth driver. Meanwhile, Lilly’s forward PE, I think, is 58 or so, maybe in the 60s.
SPEAKER 04 :
Okay, now here’s another big stunning difference between them. Lilly is now six times the size of Pfizer. Pfizer’s 140 million. Lilly’s 824 billion. Lilly is now 824 billion. Lilly’s going to make $29 per share in their coming 12 months. Pfizer’s going to make $3 per share. So I would just say that the Dow should be a little bit more actively managed. I’m not talking about trading stocks in and out, but when a company blows by Pfizer like it did many years ago and leaves Pfizer in the dust, and Merck’s not much better, really. Merck has done a little bit better than Pfizer, but not much. Okay, so Lilly reports earnings. Last night, obviously their ZEP bound has doubled. Their sales have doubled. Overall, their sales were up 45% as Lilly closes in on a trillion dollars, which I predicted a few years back. I said Lilly will become the first trillion dollar pharmaceutical, the first trillion dollar drug stock. There’s nothing that can really hold it back. It’s going to do it. just based on it should be an easy thing for Lilly to do at this point in time. That’s only like 20% away from where it is now. Their earnings were up 114%. Listen to their last four quarters. Earnings up 59%, earnings up 86%, earnings up 999%, and earnings up 114%. Take that Pfizer, take that Merck, take that Bristol-Myers Squibb and all the other drug stocks that really haven’t had much for a long, long time. Look at the move in Lilly today. It’s breaking out. It’s really got its mojo back. It went through a few tough quarters there. Last year, the competition coming in from the compounders trying to keep up with supply, right? They couldn’t keep up – or demand. They couldn’t keep up with demand for the drug. The only issue I would say that they have now is the cost of – of Zepbound and Mongero. It’s not cheap. No, it’s not cheap, but either is going to the gym and working out and dieting and all the other things that come along with trying to lose weight. And I would argue that when one is on this, your food bill goes way down. Eating out, going to the grocery store, let alone your health care costs. So I obviously am a big, big proponent of both Lilly and Novo Nordisk. Lilly is in our premier growth portfolio. It was our largest holding there until it kind of took a dip. I did sell half. We had a 10% weighting in Lilly.
SPEAKER 03 :
Well, and it is a way to bend the cost curve, right, in the right direction for, you know, health care, which is a big expense of the government as well. And so, you know, if you can do it in a safe way, right, and then, you know, like I think RFK even mentioned that it was, you know, they were miracle drugs or what have you. I mean, obviously, everything comes with a potential side effect. But in terms of what you’ve seen, the use cases for it, most recently, what was it? Kidney disease, I believe, which is pretty remarkable.
SPEAKER 04 :
Sleep apnea. Right. Here’s the astonishing part of this. It was just a few weeks ago that Lilly warned on the quarter that they just reported that Well, okay, they warn and they still come in with 45% growth in sales year over year. That’s pretty good. How many companies out there have 45% growth in a 12-month period of time? And the growth path looking forward… They’re not at peak growth, and they also come in with earnings growth of 114%. So, you know, with a warning like that, more companies should warn and come in with numbers like this, which are pretty phenomenal. So anyways, we’re still big fans of Lilly, and it makes total sense from a valuation point of view. I don’t think that growth has been factored into this stock at all. And it’s a dividend payer.
SPEAKER 03 :
Yeah, and Novo, I mean, even their report was good in terms of they were talking about they’ve basically been stockpiling the drug for future demand, right? I mean, all signs say that whatever they can produce will be purchased at least at this point.
SPEAKER 04 :
Yes. Now, we do have some tech stocks that have reported here today. Arm Holdings, which has been pretty perky here recently. You know, it’s a player in AI. It’s a semiconductor company out of the UK. I’ve owned it in the past. We don’t currently own it. But let’s take a little look at their report that came in last night. Also, Qualcomm. And we have Bombadier. I want to mention Bombadier and Roblox. We’ll be right back. And welcome back here to the final segment of today’s Best Stocks Now show. Before we leave Lilly, I want to go to our current valuation on Lilly. That five-year target price is pretty critical. You know, looking at track record, 31% per year over the last 10 years, 44% over the last five years. That’s looking in the rearview mirror. That’s looking at the backward set, where the company has been. As an investor, we want to know where the company is headed. And for that, the best information that we have for that is obviously the analyst estimates out there. I’m sure there’s a pretty good cadre of analysts following Lilly. They have growth right now of 18% per year over the next five years. To me, that might even be a little bit conservative. That means doubling your earnings in four years with the rule of 72% And if they’re right, I mean, and the multiple remains fair, I have a $1,700 target price on Lilly, which gives it the potential to double over the next four to five years. Obviously, that depends on Lilly, okay? And the markets and the economy and the world and all kinds of other different factors, interest rates, et cetera, inflation, right? But that’s the best we could do with the information that we have. And that makes it very attractive. So when you take those two criteria, growth are three criteria here. Past performance, which is phenomenal, A+. The valuation grade is currently A, and when I add those two together and compare it, I’m up to $5,019 in our database right now, stocks, ETFs, mutual funds. Lilly comes in at number 33. And that’s a combination of performance, momentum, and it has a good chart, and valuation, which is looking forward, okay? So very nice report from Lilly, in my opinion, and there’s no reason to be. We still have it as a strong buy at this level. Okay, next. This is one I’ve never talked about. I don’t know. Not in recent years. There’s two major airplane makers in the world. One is Boeing, and the other is Airbus, okay? But we talked yesterday, or yeah, yesterday, Embraer is number three. And you drop down a little notch for Embraer. They make a lot of the regional jets, okay? That’s kind of their niche. And they make these flex jets, okay, private jets. Now, let’s go to another one up in Canada that doesn’t get a lot of hoopla but has performed rather well. And I did add it. For some reason, it wasn’t in my app, and it should be. Bombardier makes Learjets, I believe. Look that up, Barry. I think it’s Learjets or Gulfstream jets, private jets. That seems to be, they seem to be in very high demand right now. BDRBF is the symbol. And the stock itself is up today. And if you look at a five-year chart of Bombardier, it’s pretty good. Now, Bombardier is not an ADR. It doesn’t trade. It doesn’t have a U.S. symbol, which would be a three-letter symbol on the S&P, or it would be a four-letter symbol if it were in the NASDAQ.
SPEAKER 03 :
Bombardier has a five-wheeler. A lot of their planes are going to hold between 12 to 19, 10 to 19 folks.
SPEAKER 04 :
Yes, corporate jets. Which, you know, if I ever go shopping for a corporate jet, we’ll test fly a Bombardier down the Wando River, right? Hopefully not end up in the Ravenel Bridge here.
SPEAKER 03 :
We’ve had clients who have had them. It turns out it’s better to rent them than own them.
SPEAKER 04 :
We have clients that fly them.
SPEAKER 03 :
Right, exactly.
SPEAKER 04 :
Four famous people, right? And so anyways, we have one client who flew John Cougar Mellencamp and Meg Ryan around. And we have another one that flies a big horse owner. Great. I mean, he’s big time thoroughbred racehorses flying around the country to see his horses run. So that’s an interesting, you know, and I see a lot of them. I mean, you go to an airport and there’s a lot of private jets out there. I’ve had a few people come visit me and they said, well, we’ll just fly in on the private jet and we’ll meet there, Gunderson and Charleston. I said, okay, that sounds good.
SPEAKER 03 :
Yeah, now with all the, you know, with NetJets and a lot of the other, you know, companies, you know, you’ve got even more demand, you know, for the, you know, think of it as, you know, think of it as budget rental car, right, for private planes. And so it increases demand and use over time.
SPEAKER 04 :
So anyways, I added BDRBF into the app. It’s viable. You know, it trades enough shares. It’s just not going to be on, you know, and you can definitely, I’m sure, Schwab or Interactive Brokers or Robinhood. So we’ll see where it comes in on its rankings. But they reported $5 per share. That’s a big quarter for Bombardier out of Canada. So we’re going to definitely put it on our watch list. Okay, let’s see. The last one I’m going to do here today is Roblox. This has been a hot stock. It’s been a momentum stock. I don’t think Roblox, I’m going to look right now, I don’t think they’re profitable yet. They’re still reporting losses. They reported another loss. This stock is down 12.9% today. So even though they’ve got 20%, 30% sales growth, And I’m sure your teens there, Barry, mess around a bit with the Roblox.
SPEAKER 03 :
I was going to say, I can’t tell you the last time I’ve seen them use Roblox. Well, neither can the market. Maybe that makes sense. Maybe that makes sense when you look at the market today.
SPEAKER 04 :
Something’s wrong because they’re down 13%. They’re losing one-sixth of their value today. But it is a money-losing stock. But that’s a $43 billion company. Let’s not laugh and sneeze at it.
SPEAKER 03 :
Down 13% today. They need to turn profitability.
SPEAKER 04 :
They’ve been cut in half since 2021. All right, well, we’re out of time for today. You still got that opportunity for the four-week trial. Spend the day with Gunderson from the trading pits at Gunderson Capital Management, where I spend most of my day in the bunker. No incoming calls. I have my game face on. Sometimes I have my helmet sandbags out. Like on those days when, you know, the Nasdaq’s getting clobbered. Things like this. But anyways, go to GundersenCapital.com for free weeks to trade along with me or follow, learn, whatever. Observe. paper trade uh or you just say you know i’m just ready to let them have them manage our money let’s interview them go to 855-611-BEST 855-611-BEST have a great day everybody
SPEAKER 02 :
This show is not a solicitation to buy or sell any securities. Bill Gunderson or clients of Gunderson Capital Management may have long or short positions in stocks mentioned during the show. Past performance is not indicative of future performance. Gunderson Capital Management is a fee-based registered investment advisory firm. All accounts are held at Charles Schwab. Schwab is a member of SIPC and FINRA.
